GCC Dry Age-Related Macular Degeneration (AMD) Market Research Report By Stage (early age-related macular degeneration, intermediate age-related macular degeneration, late age-related macular degeneration), By Age Group (above 75 years, above 60 years, above 40 years), By Diagnosis and Treatment (treatment, diagnosis), By Route of Administration (oral, injectables) and By End Users (hospitals clinics, diagnostic centers, academic research institutes) - Forecast to 2035

GCC Dry Age-Related Macular Degeneration (AMD) Market Overview

As per MRFR analysis, the GCC Dry Age-Related Macular Degeneration (AMD) Market Size was estimated at 110.0 (USD Million) in 2023. The GCC Dry Age-Related Macular Degeneration (AMD) Market Industry is expected to grow from 120.0(USD Million) in 2024 to 300.0 (USD Million) by 2035. The GCC Dry Age-Related Macular Degeneration (AMD) Market CAGR (growth rate) is expected to be around 8.687% during the forecast period (2025 - 2035).

Key GCC Dry Age-Related Macular Degeneration (AMD) Market Trends Highlighted

The GCC Dry Age-Related Macular Degeneration (AMD) market is witnessing significant trends driven by various factors. An aging population is one of the key market drivers, as countries in the GCC, such as Saudi Arabia and the UAE, are experiencing a rising demographic of older adults. This demographic shift increases the prevalence of AMD, consequently creating a higher demand for diagnostic tools and treatment options tailored to this condition. Furthermore, increased awareness and education about AMD, supported by health campaigns from local governments, are leading to early detection and intervention, which are crucial given the progressive nature of the disease.

The GCC Dry Age-Related Macular Degeneration (AMD) market is growing along with the opportunities for advanced healthcare technologies and research in the GCC region. Local health authorities are investing in facilities and sophisticated diagnostic and therapeutic devices. Furthermore, the partnership between the healthcare and the pharmaceutical industry resulted in new therapeutic innovations and better management of GCC Dry Age-Related Macular Degeneration (AMD). Moreover, telemedicine offers specialized eye care services remotely, minimizing the travel burden for patients. Recently, there has also been a noticeable shift in government support and health policies aimed at eye care enhancement.

This includes initiatives to subsidize treatments for GCC Dry Age-Related Macular Degeneration (AMD), ensuring that patients have access to necessary care. Additionally, there is a growing interest among investors in funding research and development specific to ocular conditions, further advancing the understanding and management of AMD in the region. Overall, these trends are contributing to a dynamic landscape in the GCC Dry Age-Related Macular Degeneration (AMD) market, aligning with global advancements while catering specifically to regional needs.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

GCC Dry Age-Related Macular Degeneration (AMD) Market Drivers

Increasing Elderly Population in GCC Region

The GCC Dry Age-Related Macular Degeneration (AMD) Market industry is significantly driven by the increasing elderly population within the region. Reports indicate that by 2035, the number of individuals aged 65 and above in the GCC is expected to rise to over 5 million, accounting for nearly 12% of the total population. This demographic shift is crucial as aging is a primary risk factor for dry AMD. Organizations like the Gulf Cooperation Council Health Ministers Council have acknowledged this trend in various health policy documents, emphasizing the necessity for better senior health care services, including comprehensive eye health programs.The rising demand for AMD treatment due to the increasing elderly population presents a substantial growth opportunity for the GCC Dry Age-Related Macular Degeneration (AMD) Market, as more individuals will seek preventive and corrective measures related to age-associated vision impairments.

Advancements in Treatment Options

The ongoing technological advancements in treatment options for dry AMD are propelling the growth of the GCC Dry Age-Related Macular Degeneration (AMD) Market industry. Innovations such as the development of new pharmacological treatments and enhanced diagnostic technologies are reshaping how dry AMD is approached. According to the World Health Organization and various regional health authorities, these advanced treatments are expected to lead to a higher success rate in managing AMD symptoms among patients, thereby increasing patient enrollments in treatment programs.The establishment of medical research centers and collaborative healthcare initiatives across GCC countries, funded by national healthcare vision plans, further supports this advancement. As a result, a growing array of treatment options attracts investment and specialization within the GCC Dry Age-Related Macular Degeneration (AMD) Market.

Rising Awareness of Eye Health

Increased public awareness regarding eye health and the effects of dry AMD is having a significant impact on the GCC Dry Age-Related Macular Degeneration (AMD) Market industry. Educational campaigns conducted by health ministries and organizations such as the Qatar National Health Strategy emphasize the importance of regular eye check-ups and early detection. With statistics showing that nearly 41% of the GCC population is unaware of their susceptibility to vision disorders, health authorities are committed to raising this awareness to improve health outcomes.Greater emphasis on preventive healthcare encourages individuals, particularly the elderly, to seek medical advice and screening for AMD, leading to increased market demand as early diagnosis and treatment options become prioritized within the GCC Dry Age-Related Macular Degeneration (AMD) Market.

GCC Dry Age-Related Macular Degeneration (AMD) Market Segment Insights

Dry Age-Related Macular Degeneration (AMD) Market Stage Insights

The GCC Dry Age-Related Macular Degeneration (AMD) Market represents a vital area of focus within the broader healthcare industry in the region, specifically relating to the Stage segment, which encompasses early, intermediate, and late age-related macular degeneration. The increasing prevalence of AMD, particularly with an aging population, has made the understanding of this segment critical for both medical practitioners and health policymakers. 

Early age-related macular degeneration is often asymptomatic, yet it establishes the foundation for further progression; hence, early detection and intervention are essential in potentially preventing vision loss.Moving to intermediate age-related macular degeneration, this stage becomes more significant as patients often experience noticeable symptoms that may prompt them to seek medical advice, creating opportunities for healthcare interventions aimed at slowing the progression of the disease. Finally, late age-related macular degeneration is particularly impactful, as patients may face severe vision loss, leading to a significant decline in quality of life, thereby amplifying the urgency for effective therapeutic treatments and support systems. 

The GCC region, as a melting pot of diverse cultures and lifestyles, is witnessing a growing awareness regarding AMD, influencing the healthcare sector to focus on innovative treatment modalities.In the context of market growth, each stage offers its unique challenges and potential for advancement in medical research, therapeutic developments, and healthcare policies aimed at AMD management. Moreover, with governmental initiatives aimed at improving eye health services and increasing public awareness programs about age-related eye diseases, the GCC Dry Age-Related Macular Degeneration (AMD) Market is expected to continue evolving in responsiveness to the needs of its aging population, yielding significant opportunities for stakeholders in health sectors, pharmaceuticals, and medical technology.The segmentation by Stage not only aids in tailoring appropriate interventions and public health strategies but also serves to drive ongoing research and dialogue around AMD, making it a critical focus area in the GCC healthcare landscape.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Dry Age-Related Macular Degeneration (AMD) Market Age Group Insights

The GCC Dry Age-Related Macular Degeneration (AMD) Market showcases significant insights, particularly when analyzed through the lens of age groups. As the population ages, the prevalence of AMD increases notably among individuals above 75 years, representing a critical demographic that demands focused healthcare strategies and solutions. Similarly, those above 60 years are becoming increasingly relevant as advancements in healthcare allow for higher life expectancy, subsequently amplifying the incidence of AMD. This age group often faces challenges related to early diagnosis and access to effective treatments, impacting the overall market dynamics.Furthermore, the segment above 40 years is also gaining attention as lifestyle factors begin to influence eye health, leading to an earlier onset of symptoms. 

The GCC region is increasingly investing in healthcare infrastructure to address the rising AMD statistics among these age demographics, creating numerous opportunities for growth in the market. Increased awareness campaigns and proactive healthcare measures are essential in addressing the unique needs of each age group, which will significantly influence the GCC Dry Age-Related Macular Degeneration (AMD) Market dynamics in the coming years.Overall, understanding the Age Group segmentation reveals critical trends and growth drivers in this evolving field.

Dry Age-Related Macular Degeneration (AMD) Market Diagnosis and Treatment Insights

The GCC Dry Age-Related Macular Degeneration (AMD) Market is witnessing a notable transformation in its Diagnosis and Treatment segment, driven largely by the region's increasing elderly population and rising prevalence of visual impairments. With advancements in diagnostic technologies, healthcare providers are able to detect Dry AMD at earlier stages, leading to more effective treatment options and better patient outcomes. The Treatment aspect is gaining traction due to innovative therapies that focus on halting disease progression and improving vision, which is crucial in managing this chronic condition.

Furthermore, the growing awareness of eye health and the importance of regular check-ups is encouraging more individuals to seek timely diagnosis, thus fueling demand. The GCC's healthcare infrastructure is continuously evolving, supported by government initiatives aimed at enhancing ophthalmic care, which augments the overall growth of the Diagnosis and Treatment market. Overall, this segment remains significant as it addresses the regional healthcare challenges posed by dry AMD, emphasizing the urgent need for comprehensive care strategies and collaborative efforts among healthcare professionals.

Dry Age-Related Macular Degeneration (AMD) Market Route of Administration Insights

The GCC Dry Age-Related Macular Degeneration (AMD) Market is increasingly focusing on the Route of Administration, highlighting the significance of both oral and injectables. Oral administration is favored due to its non-invasive nature, thereby enhancing patient compliance and accessibility, which is essential in a region where healthcare services aim for maximum outreach. On the other hand, injectables are notable for their targeted delivery and rapid action, characteristics that are crucial in managing AMD, a prevalent condition among the aging population in the GCC region.This demographic shift towards a higher percentage of older individuals directly influences the demand for effective AMD treatment, creating a lucrative atmosphere for these administration routes. 

The GCC's healthcare sector is undergoing significant transformation, fostering innovative solutions and advanced therapeutic options that prioritize patient convenience and treatment efficacy. Increasing healthcare investments and awareness of AMD are driving market growth across the region. While oral medications play a vital role in long-term management, injectables dominate due to their fast-acting and high efficacy profiles, thereby creating a balanced landscape of treatment options that address both immediate and chronic management needs in AMD.

Dry Age-Related Macular Degeneration (AMD) Market End Users Insights

The 'GCC Dry Age-Related Macular Degeneration (AMD) Market' focuses on various end users that play pivotal roles in managing this condition. Hospitals and clinics stand out as primary providers, offering essential services for diagnosis and treatment, which significantly contributes to the market’s growth. Diagnostic centers are vital as they specialize in specialized testing and early detection, greatly influencing patient outcomes and facilitating timely interventions. Meanwhile, academic and research institutes drive innovation and progress in the AMD landscape through studies and advancements in treatment methodologies, contributing to improved quality of care.

Together, these segments not only cater to the growing patient population in the GCC region, where aging demographics are expected to rise but also emphasize the importance of targeted interventions and enhanced awareness regarding AMD. Overall, the collaborative synergy among these end users supports comprehensive care pathways, reinforcing their significance within the GCC Dry Age-Related Macular Degeneration (AMD) Market landscape.

GCC Dry Age-Related Macular Degeneration (AMD) Market Key Players and Competitive Insights

The GCC Dry Age-Related Macular Degeneration (AMD) Market is characterized by a competitive landscape defined by a mix of established pharmaceutical companies and emerging biotech firms. This market is gaining traction owing to a rapidly increasing aging population, increased awareness regarding eye health, and advancements in treatment modalities. As the prevalence of AMD continues to rise in the Gulf Cooperation Council region, companies in this space are focusing on product innovation, strategic partnerships, and market penetration strategies to capitalize on the growing demand for effective AMD treatments. 

The competitive insights reveal a dynamic environment where companies are leveraging research and development initiatives to introduce novel therapies and improve patient outcomes while adapting to the specific needs of the GCC market.Focusing on Bayer within the GCC Dry Age-Related Macular Degeneration (AMD) Market, the company has successfully established a robust market presence with a comprehensive portfolio of ophthalmic pharmaceuticals. Bayer's strengths lie in its extensive experience in the healthcare sector, backed by significant investment in research and development tailored towards AMD treatment. 

The company is known for its rigorous RD initiatives that focus on delivering innovative solutions that cater to the specific needs of patients in the region. Bayer's established relationships with healthcare providers and regulatory authorities in the GCC further bolster its market standing, allowing for quick product adoption and effective positioning in a competitive market landscape. This solid foundation enables Bayer to leverage its expertise to address the growing burden of AMD effectively.When considering Zymeworks in the context of the GCC Dry Age-Related Macular Degeneration (AMD) Market, the company has carved out a niche for itself by focusing on innovative therapies that target unmet medical needs. Zymeworks is noted for its proprietary Zymeworks' technology platform, which is designed to accelerate the development of new treatments for eye diseases, including AMD. 

The company's market presence is strengthened by its strategic collaborations and partnerships that facilitate access to essential resources and enhance its research capabilities within the GCC. Zymeworks's focus on precision medicine and the customization of therapeutic options positions it favorably amidst competitors, especially with an emphasis on patient-centric solutions. Additionally, Zymeworks actively explores mergers and acquisitions to expand its portfolio and capabilities, which further solidifies its position within the rapidly evolving AMD market in the GCC region.

Key Companies in the GCC Dry Age-Related Macular Degeneration (AMD) Market Include:

• Bayer


• Zymeworks


• Genentech


• Amgen


• Roche


• Karyopharm Therapeutics


• EyePoint Pharmaceuticals


• Alcon


• Pfizer


• Iveric Bio


• Novartis


• Santen Pharmaceutical


• Hoffmann la Roche


• Regeneron Pharmaceuticals


• Apellis Pharmaceuticals

GCC Dry Age-Related Macular Degeneration (AMD) Market Industry Developments

In the GCC Dry Age-Related Macular Degeneration (AMD) Market, recent developments include the continued focus on innovative treatments from key players such as Bayer and Genentech, as they strive to enhance therapeutic options for patients dealing with this condition. In October 2023, Regeneron Pharmaceuticals launched a new formulation for their AMD treatment, aiming to improve patient compliance and outcomes. The market has also experienced growth in valuation driven by increasing awareness of AMD, which is reflected in recent health initiatives led by local governments across the GCC to prioritize eye health. 

Additionally, mergers and acquisitions are making headlines, with Zymeworks announcing discussions for strategic partnerships to expand its AMD portfolio in December 2022. The GCC region has seen rising investments in ophthalmic research, particularly from companies like Alcon and Roche, indicative of the market's potential. The increased prevalence of AMD among the aging population in this region has been a key driver, prompting companies to accelerate their research and development efforts. Long-term studies conducted in various GCC countries since 2021 have highlighted the need for effective care strategies, showcasing the urgent demand for advancements in AMD management.

GCC Dry Age-Related Macular Degeneration (AMD) Market Segmentation Insights

• Dry Age-Related Macular Degeneration (AMD) Market Stage Outlook
  
  
  
  • early age-related macular degeneration
  
  
  • intermediate age-related macular degeneration
  
  
  • late age-related macular degeneration
  
  
  
  

• Dry Age-Related Macular Degeneration (AMD) Market Age Group Outlook
  
  
  
  • above 75 years
  
  
  • above 60 years
  
  
  • above 40 years
  
  
  
  

• Dry Age-Related Macular Degeneration (AMD) Market Diagnosis and Treatment Outlook
  
  
  
  • treatment
  
  
  • diagnosis
  
  
  
  

• Dry Age-Related Macular Degeneration (AMD) Market Route of Administration Outlook
  
  
  
  • oral
  
  
  • injectables
  
  
  
  

• Dry Age-Related Macular Degeneration (AMD) Market End Users Outlook
  
  
  
  • hospitals clinics
  
  
  • diagnostic centers
  
  
  • academic research institutes
  
  
  
  

Report Attribute/Metric Source:	Details
MARKET SIZE 2023	110.0(USD Million)
MARKET SIZE 2024	120.0(USD Million)
MARKET SIZE 2035	300.0(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	8.687% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Million
KEY COMPANIES PROFILED	Bayer, Zymeworks, Genentech, Amgen, Roche, Karyopharm Therapeutics, EyePoint Pharmaceuticals, Alcon, Pfizer, Iveric Bio, Novartis, Santen Pharmaceutical, HoffmannLa Roche, Regeneron Pharmaceuticals, Apellis Pharmaceuticals
SEGMENTS COVERED	Stage, Age Group, Diagnosis and Treatment, Route of Administration, End Users
KEY MARKET OPPORTUNITIES	Increasing elderly population prevalence, Advancements in diagnostic technologies, Growth in telehealth services, Rising awareness and education campaigns, Expanding healthcare infrastructure investments
KEY MARKET DYNAMICS	rising elderly population, increasing healthcare expenditure, advancements in treatment options, growing awareness and diagnosis, influx of innovative technologies
COUNTRIES COVERED	GCC